The resistance of tumours to immune-mediated lysis has been linked to the biology of matrix metalloproteinases (MMPs), and specifically to the cell surface expression of MMPs by the tumour cell. The endogenous tissue inhibitors of metalloproteinases (TIMPs) exhibit diverse physiological/biological functions including the moderation of tumour growth, metastasis and apoptosis. These biologic activities are mediated in part by the stoichiometry of TIMP/MMP/cell surface protein interactions. A glycosylphosphatidylinositol (GPI) anchor was fused to TIMP-1 to focus defined concentrations of this inhibitory protein on the surface of three renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53 and A498) independently of cell surface protein-protein interactions. Exogenously added TIMP-1-GPI efficiently inserted into the RCC cell membrane and dramatically altered the association of MMPs with the cell surface. TIMP-1-GPI treatment inhibited RCC proliferation and rendered the normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis but did not alter perforin-mediated lysis by cytotoxic effector cells. The increased sensitivity to FAS-mediated apoptosis correlated with an alteration in the balance of pro-and antiapoptotic BCL-2-family proteins. By interfering with the proliferative capacity and inducing sensitivity to immune effector mechanisms GPI-anchored TIMP-1 may represent a more effective version of the TIMP-1 protein for therapeutic strategies.
Introduction
Renal cell carcinoma (RCC) is the seventh leading cause of cancer. Approximately one-third of patients with RCC have metastatic disease at presentation and up to 50% relapse following nephrectomy (Vogelzang and Stadler, 1998) . RCC is difficult to treat and immunological therapies such as interferon-alpha and interleukin-2 are generally more effective than chemotherapy or radiation (Vogelzang and Stadler, 1998) . Cytotoxic lymphocytes represent a potential component in the defense against tumours including RCC. Although cytotoxic T lymphocytes (CTL) and natural killer (NK) cells that infiltrate and recognize autologous RCC tumour are often identified (reviewed in Schendel et al., 1997) , effective antitumour immunity fails to develop. The aetiology of this functional deficiency in cytotoxic lymphocytes is currently unclear.
The antitumour effects of CTLs and NK cells are mediated through either the perforin/granzyme or CD95/ CSD95L apoptotic pathways (Kagi et al., 1994) . The perforin pathway entails the release of cytotoxins that are secreted during CTL or NK recognition of target cells (Kagi et al., 1994) . The CD95, or FAS death receptor, belongs to the regulator of cell death family of proteins and is of central importance in immune-mediated apoptosis of tumour cells (Nagata, 1999) . Many tumours including RCC have been found to be resistant to apoptosis mediated through the FAS pathway (Frost et al. (2003) , reviewed in Igney and Krammer, (2002) ).
Matrix metalloproteinases (MMPs) degrade components of the extracellular matrix (ECM) and have been implicated in tissue remodelling, tumour invasion and metastasis (Egeblad and Werb, 2002; Itoh and Nagase, 2002) . MMP activity is regulated at many levels including by the activities of the four endogenous inhibitors, the tissue inhibitors of matrix metalloproteinases (TIMP)-1, -2, -3 and 4 (Bode and Maskos, 2003) . In vivo, the balance between MMPs and TIMPs determines whether matrix resorption or deposition occurs (Nagase and Woessner, 1999) . While TIMPs inhibit MMP activity and thus inhibit tumour growth and metastasis, TIMPs are also multifunctional proteins shown to also regulate cell proliferation, apoptosis and angiogenesis. MMP or TIMP activities have been previously linked to the efficiency of both perforin/ granzyme-and FAS-mediated apoptosis (Baker et al., 1998; Bond et al., 2002; Egeblad and Werb, 2002; Ahonen et al., 2003) .
TIMP-1 is a broadly acting MMP inhibitor (Bode and Maskos, 2003) . It is a soluble protein that can sometimes be detected on the cell surface but only through its association with surface-bound proteins (Brew et al., 2000; Klier et al., 2001) . The overall role of TIMP-1 in cancer biology remains the subject of conflicting reports (Brand, 2002) . TIMP-1 has been linked to angiogenesis, cell migration, proliferation, tumour growth and metastases (Brand, 2002) .
Proteins anchored by glycosylphosphatidylinositol (GPI), when purified and added to cells in vitro, are incorporated into their surface membranes (Medof et al., 1996; Djafarzadeh et al., 2004) . This protein engineering of cell surfaces using GPI anchors has been used to explore and expand protein function (Med of et al., 1996; Djafarzadeh et al., 2004) . TIMP-1 was combined with a GPI anchor to generate a reagent that could be used to focus exogenously added TIMP-1 to cell surfaces independently of protein-protein interactions (Brown et al., 2000; Djafarzadeh et al., 2004) . The effect of exogenously added protein and the subsequent changes in protease stoichiometry on the biology and immunogenicity of RCC was studied.
Results
The RCC-26 (Schendel et al., 1993) and RCC-53 cell lines were established from local patients with stage I and stage IV clear-cell carcinomas, respectively. Thereby, they represent the two clinical extremes of RCC. Tumour-infiltrating CTLs were isolated from tumour of both patients. Although these naturally occurring effector cells were unable to control tumour growth in vivo, surface marker staining of RCC-26 and RCC-53 revealed good surface expression of MHC class I, and both lines were shown to induce allo-and antitumourspecific CTL in vitro (Schendel et al., 2000; DJ Schendel, unpublished observation) . A498 was originally isolated from the tumour of a 52-year-old male and is a wellstudied example of RCC (Giard et al., 1973) .
Incorporation of exogenously added TIMP-1-GPI into the surface of RCC-53 GPI-anchored TIMP-1 protein was generated and isolated as described previously (Djafarzadeh et al., 2004) . The incorporation of purified GPI-TIMP-1 protein into the surface membranes of RCC-53, RCC-26 or A498 RCC cell lines was demonstrated by incubation of the cell lines with 700 ng/ml of purified TIMP-1-GPI or recombinant human (rh)TIMP-1 control protein for 1 h. Surface-associated TIMP-1 protein was then detected using fluorescence-activated cell sorting (FACS) (Figure 1a) . Addition of control rhTIMP-1 did not lead to change in the FACS shift; however, GPI-anchored TIMP-1 resulted in a strong surface signal for TIMP-1.
To demonstrate that the exogenously added protein was GPI anchored, RCC-53 cells were first incubated with TIMP-1-GPI protein (200 or 700 ng/ml), and then treated with 60 ng/ml phospholipase C (PLC). FACS analysis demonstrated the complete loss of TIMP-1 cell surface signal following PLC digestion (Figure 1b) . To measure the efficiency of TIMP-1-GPI integration, the TIMP-1 freed from the membrane was collected in the wash buffers, and quantified using TIMP-1-specific ELISA (Figure 1c) . The results show that 66% of the starting TIMP-1 antigen was recovered from the 200 ng/ ml sample, while 31% could be recovered from the 700 ng/ml incubation.
TIMP-1-GPI protein blocks release of pro-MMP-2 and pro-MMP-9 from RCC-53 An increased expression of MMP-2 and MMP-9 correlates with a poor prognosis of RCC (Hemmerlein et al., 2004) . The stage IV clear-cell carcinoma cell line RCC-53 constitutively secretes both pro-MMP-2 and pro-MMP-9 (Figure 2 ). The effect of increasing surface TIMP-1 levels on the constitutive release of MMP-2 and MMP-9 proteins was tested using gelatinase zymography assays (Klier et al., 2001; Djafarzadeh et al., 2004) . rhTIMP-1 protein at 600 or 1200 ng/ml had no effect on pro-MMP-2 or pro-MMP-9 secretion. In contrast, starting at 10 ng/ml, TIMP-1-GPI treatment showed a concentration-dependent decrease of both pro-MMP-2 and pro-MMP-9 release into the growth media.
Treatment with TIMP-1-GPI leads to increase in surface expression of MMPs Based on the results of the gelatinase zymography experiments, it is possible that TIMP-1-GPI may act to sequester MMPs on the cell surface. TIMP-1 binds most active forms of MMPs, the exceptions being MMP-14 and MMP-16 (Brew et al., 2000; Lang et al., 2004) . Following incubation of RCC-53 with 700 ng/ml of TIMP-1-GPI protein for 24 h, FACS analyses using MMP-1, MMP-2, MMP-3, specific antibodies showed, with the exception of MMP-14, an increase in mean channel fluorescence intensity (MFI) for each of the MMPs. rhTIMP-1 control protein had no obvious effect on the FACS signal (data not shown). The surface expression of other proteins including MHC class I (panclass I and HLA-A2) and ICAM-1 was not effected by TIMP-1-GPI treatment. Digestion of the TIMP-1-GPI-treated RCC-53 with PLC after 1 h (as performed in Figure 1 ) showed no increase in MMPs (Figure 3a and b) . The accumulation of MMPs on the cell surface mirrored the reduction in secretion of pro-MMP-2 and pro-MMP-9 shown in Figure 2 . To further test this apparent blockade of MMP release, Western blot experiments were performed using monoclonal antibodies directed against MMP-1, MMP-3, MMP-7, MMP-8, MMP-12 and MMP-13 on media (serum free) derived from control RCC-53 cells or cells treated 24 h with 700 ng/ml of either rhTIMP-1 or TIMP-1-GPI (Figure 3c ). The presence of each of the MMPs was detected in the media from control RCC-53 cells.
Incubation with rhTIMP-1 did not eliminate secretion of the MMPs. In contrast, TIMP-1-GPI appeared to completely block the release of each MMP studied.
To assess the effect of this surface accumulation of MMPs on the ability of the cells to invade ECM, the migration/invasion capacity of the cells was tested using a modified Boyden chamber assay with ECM-coated membranes. The overall ability of the RCC-53 cells to invade ECM was not very pronounced (data not shown). To enhance invasion, increasing levels of vascular endothelial growth factor (VEGF) were applied to the lower wells and the experiments were run for 48 h. An optimal invasion response was seen at 4 ng/ml VEGF (data not shown) and this response was set as baseline invasion, or zero % inhibition ( Figure  3d ). RCC-53 cells pretreated for 30 min with 350 or 700 ng/ml of either rhTIMP-1 or TIMP-1-GPI were then washed, and applied to the top well of the Boyden chamber. The relative increase or decrease in migration/invasion was then determined (see Materials 
GPI-anchored TIMP-1 effects proliferation of RCC
We have previously shown that treatment with TIMP-1-GPI can either enhance or suppress cell proliferation depending on the specific cell type studied (Djafarzadeh et al., 2004) . To assess the effect of TIMP-1 surface engineering on the proliferation of RCC, MTT (3,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays were performed. The exogenously added TIMP-1-GPI protein was found to elicit a dose-dependent decrease in proliferation of RCC-53 and A498 at 24, 48 and 72 h (Figure 4b ). RCC-26 cells proliferate extremely slowly (48 þ h doubling rate) and, while the general trend suggested a suppression of proliferation, it was not possible to derive a definitive conclusion (Figure 4c ). Additional controls using phosphatidylinositol at an equal molar concentration to the TIMP-1-GPI reagent (Sigma, Germany, No. P6636) did not lead to significant changes in proliferation of the cells (data not shown).
Cell-mediated cytotoxicity MMP activity has been linked to the sensitivity of target cells to apoptosis induced by cytotoxic T-cell activity (both perforin/granzyme-and FAS-mediated apoptosis) (Egeblad and Werb, 2002) . The effect of TIMP-1-GPI on cell-dependent killing of RCC was tested using allogeneic CTL-and NK cell-induced apoptosis. In the allogeneic CTL-mediated assays, RCC-53, A498 and RCC-26 target cells were treated with 700 ng/ml of rhTIMP-1 or TIMP-1-GPI, then labelled with Cr51 and incubated with allogeneic CD8 þ CTL JB4 (Figure 5a ) or NK cell lines (Figure 5b ). The RCC lines were recognized and killed by both the CTL and NK cells. Treatment with TIMP-1 or TIMP-1-GPI did not alter the susceptibility of the three RCC lines to either CTL-or NK cell-mediated apoptosis.
TIMP-GPI treatment renders RCC sensitive to FAS-mediated killing
The CTL/NK experiments showed that TIMP-1-GPI treatment did not influence the perforin/granzymemediated lytic pathway measured in the chromiumrelease assay. This pathway acts quickly using the secretion of stored cytotoxins to initiate apoptosis and represents one of the two major immune-initiated cell death mechanisms (Trapani et al., 2000) . The second pathway involves FAS/CD95 ligation. The effect of TIMP-1-GPI treatment on FAS-mediated apoptosis was then determined.
FAS expression on the RCC lines was first assessed by flow cytometry using a nonactivating anti-FAS mAB (L-958) (H Engelmann, unpublished results). Untreated cells and cells treated with 700 ng/ml TIMP-1-GPI or rhTIMP-1 control protein for 24 h were stained with L-958 and analysed. FAS-protein was strongly expressed by all three RCC lines. Treatment with TIMP-1-GPI or rhTIMP-1 did not affect cell surface expression of FAS ( Figure 6a ). The anti-FAS mAB L-957 can induce apoptosis in FAS-expressing cells (H Englemann, unpublished results). The binding of annexin V-fluoroisothiocyanate (FITC) and incorporation of propidium iodide (PI) into RCC cells after treatment with L-957 was used to detect apoptosis by flow cytometry. As demonstrated in Figure 6b , RCC-26 and RCC-53 were largely resistant to FAS-mediated apoptosis. The MFI of untreated and L-957-treated cells was similar. A slight increase in MFI was seen in the RCC-53 in response to L-957 treatment. These observations are in line with previous reports that RCC is generally resistant to FASmediated apoptosis (Frost et al., 2003) . Treatment with TIMP-1-GPI (L-957 þ TIMP-1-GPI), but not control rhTIMP-1 (L-957 þ rhTIMP-1), rendered the cell lines sensitive to FAS-mediated apoptosis (Figure 6b ). A498 was found to be more sensitive to the activating anti-FAS mAB (detected by increased annexin-MFI in L-957-treated samples), TIMP-1-GPI treatment, but not rhTIMP-1, significantly enhanced apoptosis of the A498 cells.
While the RCC-26 and A498 cells showed a dramatic increase in FAS-induced apoptosis following TIMP-1-GPI treatment, the RCC-53 cell line showed a less pronounced increase in sensitivity (change in MFI from 62 to 93). To confirm the TIMP-1-GPI/FASinduced apoptosis of RCC-53, a second ELISA assay based on the detection of cytoplasmic chromatin was employed. Advantages of this assay include the lack of subjectivity in interpreting the results and its increased sensitivity relative to the annexin V stain. The chromatin ELISA is able to detect as few as 300 apoptotic cells and measures apoptosis events considerably downstream from the early presence of annexin V on the cell surface. As was found in the annexin V FACS analysis (Figure 6b) , treatment of RCC-53 with L-957 alone induced a slight increase in apoptosis (Figure 6c ). However, treatment of RCC-53 cells with TIMP-1-GPI dramatically increased sensitivity of the cells to anti-FAS-induced apoptosis in a dose-dependent manner.
Figure 2 TIMP-1-GPI inhibits release of pro-MMP-2 and pro-MMP-9 from RCC-53 cells. Zymography was used to study the secretion of MMP-2 and MMP-9 proteins from RCC-53. The cells were treated with increasing amounts of TIMP-1-GPI, or control rhTIMP-1, and after 48 h the serum-free culture supernatant was removed and analysed by gelatinase zymography.
TIMP-1-GPI treatment of RCC reduces BCL-2 and increases BAX protein expression
The BCL-2 proteins represent a family of proteins involved in the control of apoptosis (reviewed in Igney and Krammer, 2002) . Some members of this family (such as BCL-2 and BCL-XL) are antiapoptotic, while others (such as Bad or BAX) are proapoptotic. The sensitivity of cells to apoptotic stimuli can depend on the balance between pro-and antiapoptotic BCL-2 family members (Igney and Krammer, 2002) . The effect of TIMP-1-GPI treatment on the expression of BCL-2 and BAX was then determined. After a 24 h preincubation Modulation of RCC biology by TIMP-1-GPI surface engineering R Djafarzadeh et al
Modulation of RCC biology by TIMP-1-GPI surface engineering R Djafarzadeh et al with 700 ng/ml of TIMP-1-GPI or rhTIMP-1 control, RCC cells were stimulated with 1 mg/ml L-957 (or control mAB) for an additional 16 h. The level of BCL-2 and BAX protein was then determined using intracellular FACS and Western blot. In all three cell lines, treatment with TIMP-1-GPI increased expression of proapoptotic BAX, and decreased expression of antiapoptotic BCL-2. A similar pattern was seen in Western blot assays (Figure 7a-c) .
Discussion
Human RCC is a progressive tumour with limited therapeutic options due to tumour resistance to current Modulation of RCC biology by TIMP-1-GPI surface engineering R Djafarzadeh et al chemotherapeutic agents and radiation. Immunotherapies are of benefit for some patients, suggesting that RCC can be targeted by immune effector mechanisms. Tumour-infiltrating lymphocytes such as CD8 þ CTL or NK cells are often seen in renal cancer tissues and often recognize autologous tumour cells when tested in vitro (reviewed in Schendel et al., 1997) . Despite these promising observations, tumours generally continue to grow, indicating that RCC might have acquired resistance to cytotoxic mechanisms. For a productive antitumour response to occur, the immune system must not only recognize the tumour' but the cancer cells must also be susceptible to the killing mechanisms utilized by CTL or NK cells. Cancer cells have evolved various mechanisms to evade immune defences including reduced sensitivity to apoptosis (reviewed in Dunn et al., 2004) . CTL and NK cells kill their target cells by perforin/ granzyme-or FAS/FASL-dependent apoptosis (Kagi et al., 1994) . The relative importance of granule exocytosis versus FAS/FASL-mediated lytic activities for tumour control in vivo is controversial. While many studies point to a dominance of the granule exocytosis mechanism, other studies using perforin-knockout mice (Seki et al., 2002) suggest that FAS-dependent apoptosis may constitute a more prominent pathway in vivo. Therefore, it is of concern that most tumour cells, including RCC, are intrinsically resistant to FASmediated killing (Frost et al., 2003) . Rendering RCC susceptible to FAS-mediated apoptosis may represent a promising therapeutic approach.
We and others have previously shown that the engineering of cells by exogenous addition of GPI-TIMP-1 can elicit enhanced as well as novel TIMP-1 biologic activities (Brown et al., 2000; Djafarzadeh et al., 2004) . Exogenously administered TIMP-1-GPI efficiently inserted into the cell membranes of RCCs and induced a variety of biological effects with potential therapeutic relevance.
GPI-anchored TIMP-1 protein dramatically altered the cell surface association of diverse RCC-expressed MMPs. This was mirrored by a reduced secretion of MMPs, including pro-MMP-2 and pro-MMP-9, from the RCC cells. This effect is intriguing and difficult to explain with regard to MMP-2 and MMP-15. While TIMP-1 will block the enzymatic activity of MMP-2, it is not thought to bind to the proform of the enzyme. Yet, the data demonstrating a blockade of pro-MMP-2 secretion following TIMP-1-GPI treatment are suggestive of this action. It appears that addition of a GPI anchor to TIMP-1 leads to an altered surface stoichiometry and enhanced capacity of the TIMP-1 protein to bind MMPs. Similar results were recently reported by us in an osteosarcoma cell line (Djafarzadeh et al., 2004) .
This apparent increased binding of TIMP-1-GPI was also suggested with membrane-type MMPs. While not much is known about TIMP-1 association with MMP-15, binding of TIMP-1-GPI protein to MMP-16 would not be predicted to occur based on the rather poor avidity of native TIMP-1 for this protein (Lang et al., 2004) . However, recent structural studies have identified the amino acids that apparently explain this low association reaction/affinity (Lang et al., 2004) . Mutational analysis of the TIMP-1 loops critical for MMP-16 binding show that small, apparently insignificant changes in TIMP-1 can dramatically shift its inhibitory/binding characteristics (Lang et al., 2004) . In this instance, the altered stoichiometry of TIMP-1 on the cell surface appears to have been sufficient to shift its binding to MMP-16. The sequestering of MMPs on the cell surface was also associated with a reduced capacity of RCC-53 cell line to undergo ECM invasion. We have previously shown that microvascular endothelial cells show a reduced capacity to undergo migration when treated with TIMP-1-GPI (Djafarzadeh et al., 2004) . Similar blockades of ECM invasion were also found for the RCC-26 and A498 cell lines (data not shown).
TIMP-1-GPI treatment leads to a pronounced dosedependent reduction in proliferation of the RCC lines. Perhaps most significantly, the normally FAS-apoptosis-resistant RCC lines were rendered sensitive to FAS/ CD95-mediated killing following treatment with the TIMP-GPI protein. However, the agent did not affect sensitivity to the perforin pathway.
The FAS-apoptosis pathway is regulated by caspase activation, while the cellular membrane damage by CTL/NK utilizing granule exocytosis, as measured by the chromium-release assay, occurs independent of caspases (Sayers et al., 1998; Trapani et al., 2000; Seki These observations represent a novel action for TIMP-1, but mirror in part biologic actions described for TIMP-3 (Baker et al., 1998) .
The overexpression of TIMP-1, -2 or -3 in vascular smooth muscle cells using adenoviral vectors was found to inhibit their migration through model basement membranes (Baker et al., 1998) . The overexpression of TIMP-1 had no effect on cell proliferation, while TIMP-2 caused a dose-dependent inhibition of cell proliferation. The overexpression of TIMP-3 also caused a dosedependent inhibition of proliferation and in addition lead to apoptosis through mitochondrial membrane depolarization and leakage of cytochrome c (Baker et al., 1998 (Baker et al., , 1999 Smith et al., 1997) . TIMP-3 is the only TIMP protein that selectively binds to the surface of cells independent of association with other surface proteins (Smith et al., 1997; Majid et al., 2002) . Focusing TIMP-1 to cell surfaces via a GPI anchor leads to novel biologic actions that appear to mimic effects reported for TIMP-3.
TIMP-3 has been shown to sensitize melanoma cells to apoptosis induced by anti-FAS-antibody, TNF-alpha and TRAIL. The mechanism of action was linked to a general stabilization of FAS, TNF-RI and TRAIL-RI on the surface of the TIMP-3-treated melanoma cells (Ahonen et al., 2003) . This increased surface expression of the receptors was linked to activation of caspase-8 and caspase-3 (Ahonen et al., 2003) . In the experiments detailed here, the RCC cells did not show a change in FAS surface expression following treatment with TIMP-1-GPI (Figure 6a ). In addition, the RCC cells remained resistant to TNF-a-induced apoptosis (tested from 100 to 10 000 U/ml) irregardless of TIMP-GPI treatment (data not shown). FACS analysis of the RCC cells subsequently showed barely detectable levels of TNF-RI (p55) and TNF-RII (p75) on RCC-53 and no expression on the RCC-26 or A498 lines (data not shown). The surface expression did not change with treatment with TIMP-1-GPI. Thus, the increased sensitivity to FASmediated apoptosis following treatment with TIMP-1-GPI does not appear to be mediated through a general stabilization of death receptor proteins on the cell surface. What is clear is that treatment with TIMP-1-GPI does alter the balance of BCL-2 proteins to elicit a more 'proapoptotic' expression profile.
TIMP biology is currently being exploited for its potential application in gene therapy of specific tumours (Rigg and Lemoine, 2001; Bloomston et al., 2002; Span et al., 2004; Zacchigna et al., 2004) . The results presented here provide an additional link between tumour biology, MMP/TIMP function and apoptosis pathways. Membrane-fixed TIMP-1 may represent a more effective version of the TIMP-1 protein for use in therapeutic applications.
Materials and methods

Cell lines and cell culture
The RCC lines, RCC-53 and RCC-26, were generated by DJS (Munich, Germany) from patient samples. RCC-53, RCC-26 and A498 (American Type Culture Collection) (Giard et al., 1973) were cultured in RPMI 1640 medium (GIBCO BRL, Life Technologies GmbH, Eggenstein, Germany) supplemented with 2 mM L-glutamine (Biochrom KG, Berlin), 1 mM sodium pyruvate (GIBCO BRL, Life Technologies GmbH, Eggenstein, Germany) and 12% heat-inactivated FCS (Biochrom KG, Berlin, Germany; No. S0115). Fresh medium was given every third day and cultures were split when cells were confluent.
Cytotoxic effector cells
JB4 is an HLA-A2-alloreactive cytotoxic T effector clone generated in our own facility (EN) and is expanded by biweekly stimulation as described (Milani et al., 2005) . It is used in cytotoxicity assays on day 7 or 8 after stimulation.
The human NK leukaemic lines, NKL (Robertson et al., 1996) and NK-92 (Gong et al., 1994) , were kindly provided by CS Falk (GSF-Institute of Molecular Immunology, Munich, Germany) and cultured in medium containing 15% heatinactivated FCS and 100 U/ml recombinant IL-2. The day before use in cytotoxicity assays, the culture was adjusted to 0.3 Â 10 6 cells/ml in fresh medium.
FACS analysis
Cells were detached with 1.5 mM EDTA (Biochrom A, Berlin, Germany; No. L2113) in 1 Â PBS and incubated for 60 min on ice with antibodies specific for human: TIMP-1 (IM32L), MMP-1 (IM35L-100), MMP-3 (IM36L-100), MMP-8 (IM38L) (Calbiochem, Merck Darmstadt, Germany); MMP-9 (IM61-100), MMP-2 (IM51L) (Oncogene, Bad Soden, Germany); MMP-7 (MAB907), anti-TNF-RI, anti-TNF-RII and isotype control antibodies were used as described (Bigda et al., 1994) . Modulation of RCC biology by TIMP-1-GPI surface engineering R Djafarzadeh et al
Purification of TIMP-1-GPI protein
The TIMP-1-GPI protein was produced and purified as described previously (Djafarzadeh et al., 2004) . Briefly, human TIMP-1 was cloned from cDNA using hTIMP-1-specific primers, fused without a translation stop codon to the GPI signal sequence cloned from LFA-3 (Kirby et al., 1995; Medof et al., 1996) and subcloned into pEF-DHFR and stably introduced into DHFR-deficient Chinese hamster ovary (CHO) cells and selected as described (Mack et al., 1995) . TIMP-1-GPI-fusion protein was purified from the CHO cells by Triton X-100 detergent extraction, followed by column purification using DEAE, heparin sepharose and size exclusion (Djafarzadeh et al., 2004) .
TIMP-1 ELISA
A human TIMP-1-specific ELISA using the protocol applied according to the manufacturer's directions (MAB970, R&D Systems) was used to monitor levels of TIMP-1 in solution.
The coating anti-human TIMP-1 mAB (MAB970), biotinylated anti-human TIMP-1 detection mAB (BAF970) and rhTIMP-1 protein (970-TM) were purchased from R&D Systems GmbH (Wiesbaden, Germany).
Incorporation of TIMP-1-GPI into cell membranes RCC-53 cells (5-10 Â 10 6 cells/ml) were incubated with 200-700 ng/ml of purified hTIMP-1-GPI at 371C/5% CO 2 . The cells were then washed three times with cold PBS and analysed by FACS using human TIMP-1-specific monoclonal antibodies (see above).
GPI anchor cleavage by PLC Cells (5-10 Â 10 6 cells/ml) were incubated with 200 or 700 ng of TIMP-1-GPI or rhTIMP-1 protein in serum-free medium for 1 h at 371C by 5% CO 2 . The cells were washed three times with cold PBS and treated with 60 ng/ml phosphatidylinositolspecific PLC (Sigma-Aldrich, Taufkirchen, Germany; No. 661-9) in serum-free medium for 30 min at 371C/5% CO 2 . Cells were washed three times, and all supernatants were harvested. Proliferation RCC-53, A498 or RCC-26 cells (30 Â 10 3 /100 ml medium) were cultured in 96-well microtitre plates for 24 h under standard conditions to yield firmly attached and stably growing cells. After discarding supernatants, 50 ml of medium containing TIMP-1-GPI, buffer or rhTIMP-1 was added to cells and incubated for 24-72 h. Then, 50 ml of a 1 mg/ml solution of MTT (Sigma-Aldrich, Taufkirchen, Germany; No. M2128) was added. After 3 h incubation at 371C, formazan crystals were dissolved by the addition 100 ml isopropanol and 0.04 N HCl. Absorbance was then measured at 550 nm using GENios plus TECAN ELISA reader. For each experiment, at least six wells were analysed per experimental condition and time point.
Zymography RCC-53 cells were cultured in 24-well plate (5 Â 10 4 cells/well). The medium was exchanged for 24 h with serum-free medium containing either rhTIMP-1 or increasing amounts of TIMP-1-GPI and incubated for 24, 48 and 72 h. Cell supernatants were analysed by gelatin zymography using 10% SDS-polyacrylamide gels (Invitrogen, Groningen, the Netherlands; No. EC61755BOX) as described (Djafarzadeh et al., 2004) . Recombinant MMP-9 enzyme (Amersham Biosciences, Uppsala, Sweden; No. RPN2634) was used as positive control.
Extracellular invasion assay
The effect of TIMP-1-GPI versus rhTIMP-1 treatment on the ability of the cells to invade ECM was evaluated using a commercial cell invasion assay (Chemicon International Inc., Temecula, CA, USA; No. ECM 555). RCC-53 cells were first analysed for their ability to invade ECM. Invaded cells in the bottom of the insert were detached, lysed and detected by CyQuant dye as described in the accompanying protocol. Increasing levels of VEGF 2-8 ng/ml was used to enhance invasion. Optimal migration was seen at 4 ng/ml VEGF (data not shown). The effect of treatment with 350 and 700 ng/ml of control rhTIMP-1 or TIMP-1-GPI on migration was then determined. To quantify the potential effects of the TIMP agents, baseline migration of the RC-53 cells to 4 ng/ml VEGF was set as 0. The value for 100% 'inhibition' to VEGF-induced migration was set as the migration/invasion of RCC-53 cells in the absence of VEGF. The resultant effects of rhTIMP or TIMP-1-GPI treatment on RCC-53 invasion were calculated as the percent change (negative or positive) relative to the 'maximal' value.
Annexin V detection of apoptosis Detection and quantification of apoptotic versus necrotic cells at the single-cell level was performed using annexin V-FLUOS staining kit (Becton, Dickinson and Company, Heidelberg, Germany; No. 556547) . RCC-53 cells were seeded at 1 Â 10 6 cells/well into 24-well plates and allowed to attach overnight. The wells were then rinsed three times with 1 Â PBS and 1 ml of serum-free RPMI 1640 medium was added, followed by 700 ng/ml of TIMP-1-GPI or rhTIMP-1. Cells were incubated for 24 h at 371C/5% CO 2 . After 24 h, 1 mg/ml anti-FASactivating mAB L-957 (H Engelmann, unpublished data) or isotype control were added and the cells were further incubated for 16 h at 371C/5% CO 2 . The cells were washed with PBS, pelleted and resuspended in staining solution (annexin Vfluorescein-labelling reagent and PI in HEPES buffer) for 15 min at room temperature. The cells were then analysed by flow cytometry. A time-course study showed that annexin-V binding in RCC cells precedes PI reactivity.
Measurement of apoptosis by chromatin-specific ELISA Apoptosis was measured using the Cell Death Detection ELISA Plus kit from Roche (Pensberg, Germany; No. 1774425) . RCC-53 cells were seeded into a 96-well dish at a concentration of 4 Â 10 4 cells/well and allowed to attach overnight. The wells were rinsed three times with 1 Â PBS and 200 ml of serum-free RPMI 1640 medium was added to each well, followed by 700 ng/ml of TIMP-1-GPI or rhTIMP-1. The cells were then incubated for 24 h at 371C/5% CO 2 . After 24 h incubation with TIMP-1-GPI or rhTIMP-1, 1 mg/ml activating anti-FAS mAB L-957 or isotype control mAB were added and incubated for 16 h at 371C/5% CO 2 . Then, the plate was centrifuged and the supernatant was carefully removed. The cell pellet was placed into 200 ml of lysis buffer provided by the manufacturer for 30 min and centrifuged. Aliquots of the supernatant (20 ml) were used in an ELISA with anti-DNA and anti-histone antibodies to detect the presence of cytoplasmic nucleosomes.
Western blot
Western blot was used for the detection of MMPs in serumfree growth media. The anti-MMP antibodies used are described above (FACS analysis). rhMMP Western blotting standards were purchased from R&D Systems (Minneapolis, USA) and included: MMP-1 (WBC024), MMP-2 (WBC025), MMP-3 (WBC015), MMP-8 (WBC017), MMP-12 (WBC019) and MMP-13 (WBC020). Western blot was also used for the detection of BCL-2, BAX (see above for mABs) and b-actin (Acris Hiddenhausen, Germany; No. ab8227). All proteins were detected using a commercial Western blot analysis kit, Chemiluminescent Immunodetection System (Invitrogen, Groningen, the Netherlands).
Cell-mediated cytotoxicity Target cells were labelled with 51 Cr for 1-2 h, washed and coincubated with effector cells at a constant cell number of 2000 cells/well in 96-V bottom plates. Duplicate measurements of four-step titrations of effector cells were used in all experiments. Spontaneous and maximum releases were determined by incubating the target cells alone and by directly counting labelled cells, respectively. After 4 h of incubation at 371C in a humidified 5% CO 2 atmosphere, supernatants were harvested, transferred to Lumaplate solid scintillation microplates, dried overnight and counted on a TopCount microplate scintillation counter (Packard, Meriden, CT, USA). For each E:T ratio, the percentage of lysis was calculated as follows: % specific lysis ¼ (experimental c.p.m.Àspontaneous c.p.m./maximal c.p.m.Àspontaneous c.p.m.) Â 100. Spontaneous release of target cells was always o15% of the total maximal release.
